Clinical Trials
24 trialsNatural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Akouos, Inc.
Vestibular Schwannoma Organoids
Maastricht Radiation Oncology
QOL-DR-NEUROMA
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
University Hospital, Geneva
Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot Study
Medical University of Vienna
Intraoperative EABR for Decision Making
Medical University of Vienna
VOVS
Haukeland University Hospital
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Leiden University Medical Center
MR Fingerprinting for Vestibular Schwannomas
Medical University of Vienna
Vegetative Monitoring During Brainstem-associated Surgery
University Hospital Tuebingen
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy
Stanford University
Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base
Taipei Veterans General Hospital, Taiwan
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
National Institutes of Health Clinical Center (CC)
SBN
University College, London
PANQOL
University Hospital, Bordeaux
Clinical and Radiological Evaluation of Acoustic Neuromas With Spontaneous Shrinkage
University Hospital, Strasbourg, France
EVTSVCGEC
University Hospital, Grenoble
NF2
University Hospital Tuebingen
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
University Hospital, Strasbourg, France
SPEED
Assistance Publique Hopitaux De Marseille
Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging
Seoul National University Hospital
Vestibular Schwannoma and Psychological Factors
Central Hospital, Nancy, France
NF2 Natural History Consortium
Office of Rare Diseases (ORD)